Health Blueprint

Back to Longevity News

News summary

Sironax to present early clinical success for experimental ALS, nerve-damage drug

Source: Longevity Technology • Published: 30 Oct 2026, 10:31

Summarized by Masters of Longevity from Longevity Technology.

Early human and preclinical data reported safety and neuroprotective signals for SIR2501.

Sironax to present early clinical success for experimental ALS, nerve-damage drug
Key Takeaways
  • SIR2501 showed favorable safety and predictable pharmacokinetics in humans.
  • SIR2501 produced neuroprotection in multiple preclinical nerve-damage models.
  • Phase 1b/2 trials in ALS and chemotherapy neuropathy are ongoing.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickNucleotides and Longevity: Is the Evidence Ready?They help build DNA and keep cells working. Early human studies make nucleotide supplements interesting—but leave important questions about healthy ageing unanswered. Yet.